Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Cervical cancer occurs in the cells of the cervix. Pap smear, colposcopy, and ECC test are performed for the diagnosis of cervical cancer. Increasing awareness regarding cervical cancer and increasing prevalence of cervical cancer in emerging economies are expected to drive growth of the market during the forecast period. For instance, according to the American Cancer Society, around 13,800 new cases of invasive cervical cancer were estimated to be diagnosed in the U.S. in 2020 and the disease was estimated to lead to death of 4,290 women in the same year.
The global cervical cancer diagnostic tests market is estimated to be valued at US$ 5,910.2 million in 2020 and is expected to exhibit a CAGR of 6.2 % over the forecast period (2020-2027).
Figure 1. Global Cervical Cancer Diagnostic Tests Market Share (%) in Terms of Value, By Region, 2020
High prevalence of HPV infected patients and rising incidence of teenage sexual encounters are expected to drive the market growth over the forecast period
Human Papillomavirus (HPV) is the largest risk factor for cervical cancer. According to the World Health Organization, two types of HPV, HPV 16 and 18, cause approximately 70% of cervical cancers and pre-cancerous cervical lesions.
Also, according to the Centers for Disease Control and Prevention, 9 out of 10 cervical cancers are caused due to Human Papillomavirus (HPV) and around 11,000 cases of cervical cancer are caused by Human Papillomavirus (HPV) every year in the U.S.
Moreover, Human Papillomavirus (HPV) is majorly transmitted through sexual contact and cervical cancer is caused by certain types of HPV acquired through sexual contact.
A cross-sectional, multicentric, nationwide survey was conducted between September 2016 and November 2017 in Brazil to evaluate the prevalence of HPV infection in sexually active adolescents and young adults. According to the survey, the mean age of first sexual intercourse was 15.3 years in women and 14.9 years in men.
Cervical Cancer Diagnostic Tests Market Report Coverage
||Market Size in 2020:
||US$ 5,910.2 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 9,010.4 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Test Type: Pap Smear Test, Colposcopy Test, ECC Test, HPV Test
- By Age Group: Age 20 – 40, Age Above 40
DYSIS Medical Ltd., Abbott Laboratories, Becton, Dickinson and Company, The Cooper Companies, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Quest Diagnostics, Arbor Vita Corporation, Hologic, Inc., Zilico Ltd, and Qiagen
- Increasing prevalence of cervical cancer
- High prevalence of human papillomavirus (HPV) infected patients and rising incidence of teenage sexual encounters
|Restraints & Challenges:
- Alternative cervical cancer diagnosis method
- HPV vaccination
Figure 2. Global Cervical Cancer Diagnostic Tests Market Share (%), By Test Type, 2020
Increasing prevalence of cervical cancer is expected to drive the market growth over the forecast period
For instance, according to the Cancer Research UK, around 3,152 new cases of cervical cancer were diagnosed during 2015 to 2017 in the U.K. and around 852 deaths were reported during the same time interval in the U.K.
Thus, increasing prevalence of cervical cancer is expected to drive the market growth over the forecast period.
Global Cervical Cancer Diagnostic Tests Market– Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector which has been majorly impacted by the pandemic.
The lockdown in various countries due to the pandemic has placed an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to declining outpatient visits, manpower, equipment, consumables, and other resources to ensure safety in treatment of patients with other diseases.
Moreover, the coronavirus pandemic has negatively impacted development, production, and supply of drugs and affected businesses of various companies operating in the healthcare sector across the globe. The pandemic has led to closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of products.
Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets.
Supply chain and manufacturing activities in India, China, U.S., and other countries have been disrupted due to lockdown while countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation of drugs and medical devices.
Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global cervical cancer diagnostic tests market during the forecast period.
Global Cervical Cancer Diagnostic Tests Market - Restraint
The major cervical cancer causing factor is HPV. Developments in the field of HPV vaccines and the vaccination of females in developed countries especially in the U.S., significantly reduces the chances of an HPV infection and hence, reduces the prevalence of cervical cancer, which is expected to hinder the market growth.
Moreover, increasing approvals of HPV vaccines by regulatory authorities is expected to hinder the growth of global cervical cancer diagnostic tests market.
For instance, in 2016, the China Food and Drug Administration (CFDA) approved Cervarix as the first HPV vaccine licensed for use in China against cervical cancer to meet the unmet needs of prevention of cervical cancers among Chinese population.
Major players operating in the global cervical cancer diagnostic tests market include DYSIS Medical Ltd., Abbott Laboratories, Becton, Dickinson and Company, The Cooper Companies, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Quest Diagnostics, Arbor Vita Corporation, Hologic, Inc., Zilico Ltd, and Qiagen.